Equities research analysts at Janney Montgomery Scott began coverage on shares of Uniqure (NASDAQ:QURE) in a report issued on Wednesday. The brokerage set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Janney Montgomery Scott’s price target suggests a potential upside of 25.57% from the company’s previous close.
Several other research analysts have also commented on QURE. ValuEngine upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a research note on Monday. BidaskClub upgraded shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. HC Wainwright assumed coverage on shares of Uniqure in a research note on Friday, December 1st. They set a “buy” rating and a $28.00 price objective for the company. Oppenheimer reiterated a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. Finally, Evercore ISI assumed coverage on shares of Uniqure in a research note on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price objective for the company. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Uniqure currently has a consensus rating of “Buy” and a consensus target price of $20.00.
Uniqure (QURE) traded up $0.09 during midday trading on Wednesday, hitting $19.91. 532,100 shares of the company traded hands, compared to its average volume of 473,567. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. The company has a market cap of $614.15, a price-to-earnings ratio of -7.63 and a beta of 0.72. Uniqure has a 1 year low of $4.72 and a 1 year high of $21.35.
In other Uniqure news, SVP Maria E. Cantor sold 5,864 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total transaction of $118,042.32. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.73% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Mangrove Partners purchased a new stake in Uniqure during the 2nd quarter worth approximately $247,000. OxFORD Asset Management LLP purchased a new stake in Uniqure during the 3rd quarter worth approximately $399,000. JPMorgan Chase & Co. grew its position in Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 14,659 shares during the last quarter. Finally, FMR LLC grew its position in Uniqure by 4.1% during the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after purchasing an additional 61,650 shares during the last quarter. 24.87% of the stock is currently owned by institutional investors.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.